MORAb-202, an antibody drug conjugate utilizing humanized anti-human FRa farletuzumab and the microtubule-targeting agent eribulin, has potent anti-tumor activity

Published 2018 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
MORAb-202, an antibody drug conjugate utilizing humanized anti-human FRa farletuzumab and the microtubule-targeting agent eribulin, has potent anti-tumor activity
Authors
Keywords
-
Journal
MOLECULAR CANCER THERAPEUTICS
Volume -, Issue -, Pages molcanther.1215.2017
Publisher
American Association for Cancer Research (AACR)
Online
2018-09-27
DOI
10.1158/1535-7163.mct-17-1215

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.